At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 110 enrolled
Drug / intervention
MEK162drug
Likely dose
MEK162 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors
In Brief
A Phase 2 clinical trial evaluating MEK162 for Solid Tumor and Hematologic Malignancies. Completed, enrolled 110 participants across 68 sites.
Detailed Summary
The purpose of this signal seeking study is to determine whether treatment with MEK162 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor and Hematologic Malignancies
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartOct 2013
Primary CompletionOct 2015
Study CompletionApr 2017
TodayJul 2026
First PostedJun 24, 2013
Enrollment StartOct 10, 2013
Primary CompletionOct 1, 2015
Study CompletionApr 11, 2017
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 13.0 years ago
Interventions
MEK162drug
MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.